european ras society

Strategic objectives

To address the complexity of RAS-driven cancers, we have defined four strategic pillars designed to integrate basic science with clinical practice and consolidate European leadership in the field.

Establish a Translational-Clinical Loop

Accelerate bench-to-bedside translation by integrating preclinical RAS models with academic clinical trials; simultaneously channel patient-derived data and hypotheses back to refine RAS preclinical research across Europe.

Federate RAS Research Across Europe

Unite ≥XX (?) leading RAS-focused labs into a cohesive network by 2028 (?), fostering joint projects, data sharing, and coordination with the NIH–NCI US RAS Initiative.

Optimize Shared Resources:

Centralize access to patient-derived materials, reagents, and high-throughput platforms to reduce duplication, lower costs, and enhance efficiency for RAS-targeting studies continent-wide.

Promote Early-Career Scientists

Mentor and support emerging RAS researchers through training programs, symposia, and funding opportunities, building the next generation of European leaders in the field.